Antiplatelet therapy prior to COVID-19 infection impacts on patients mortality: a propensity score-matched cohort study
Abstract One of the major pathomechanisms of COVID-19 is the interplay of hyperinflammation and disruptions in coagulation processes, involving thrombocytes. Antiplatelet therapy (AP) by anti-inflammatory effect and inhibition of platelet aggregation may affect these pathways. The aim of this study...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Nature Portfolio
2024-02-01
|
| سلاسل: | Scientific Reports |
| الوصول للمادة أونلاين: | https://doi.org/10.1038/s41598-024-55407-9 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|